Seattle Genetics Moves Antibody-Drug Conjugate Into Phase III For Hodgkin’s Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
SGN-35 trial kicks off in first quarter under a special protocol assessment, with an NDA filing targeted for 2011.